Who we are
The management team of NEO New Oncology
Corey R. Bouwman
Chief Executive Officer
Since autumn 2017, Corey R. Bouwman is the Chief Executive Officer at NEO New Oncology. Previously, he was responsible for Marketing, Sales, Healthcare Account Management and Strategic Market Development in the area Respiratory, Inflammation and Autoimmunity at the leading pharmaceutical company AstraZeneca as Vice President and member of the executive management. In 2009–2015, Corey held various executive management positions in Marketing, Sales, and business strategy of the pharmaceutical company Chiesi Group.
Chief Financial Officer
Together with Corey R. Bouwman, Christian Robrecht sits on the executive board of NEO New Oncology GmbH. Christian Robrecht has been with Siemens AG since 1992. After completing his degree in business management, Christian Robrecht was employed in various business units of the company and has been working in the Healthcare division since 2004. Since 2008, he is responsible for the sales and service business of the »West« region for Siemens Healthineers as a commercial manager in the German organization.
Dr. Lukas C. Heukamp (MB PhD)
Chief Medical Officer
Lukas C. Heukamp is your contact person for all questions pertaining to diagnostics and interpretation of molecular genetic test results. He is a board certified pathologist as well as a trained molecular biologist. The focus of his long-standing research is the genomic stratification of patients for novel targeted therapeutic approaches. In his capacity as joint study director of the Lung Cancer Group Cologne, Lukas C. Heukamp was involved in the routine molecular pathological diagnosis of more than 3,000 cancer patients per year. He is the author of numerous peer-reviewed publications on targeted cancer therapies and molecular diagnostics.
Prof. Dr. med. Roman Thomas
Roman Thomas is a key scientific advisor to New Oncology. As the Head of the Translational Genomics Department at the University of Cologne, his research activities have characterised over a thousand tumours. His scientific focus is on genetically testing cancer-relevant gene mutations, deciphering their mode of action, and analysing their impact on the sensitivity of tumors to new cancer drugs. Roman Thomas received the German Cancer Prize in 2013 for his contributions to the field of translational cancer research.
Prof. Dr. Axel Ullrich
Axel Ullrich is the Director of the Max Planck Institute for Biochemistry in Martinsried. He is one of the leading cancer researchers worldwide with ground breaking pioneer work on the development of targeted cancer therapy. In the mid-1980s he initiated the HER2 project at Genentech and identified antibodies that led to the development of Herceptin®. Primarily used to treat patients with breast cancer, Herceptin® was the first targeted cancer drug approved by the FDA. The second targeted cancer drug based on the research of Axel Ullrich is Sutent®, a multi-specific cancer drug used to treat gastrointestinal cancer (GIST) and kidney cancer. Axel Ullrich has received many awards for his research, including the German Cancer Aid Prize and the Federal Cross of Merit First Class.
Dr. Jutta Fritz
Chief Business Officer
Jutta Fritz is your contact person pertaining to all questions regarding cooperation. She is a molecular biologist and for a number of years was responsible for the business development of the biotechnology company Kinaxo. Subsequently, she became Vice President of Business Development at Evotec AG, leading the proteomics division, which sought to elucidate the mode of action of oncological drugs. Jutta Fritz was responsible for numerous collaborations in the field of drug testing.
Dr. Johannes Heuckmann
Chief Scientific Officer
Johannes Heuckmann is your contact person for all scientific and technical questions on molecular genetic testing, data processing and data analysis. He is a biomedic who specializes in the field of functional cancer genomics. Johannes Heuckmann is the co-author of numerous international research papers and has been instrumental in developing our diagnostic NEO technology.
Dr. Christian Glöckner
Chief Technology Officer
Christian Glöckner is responsible for establishing and implementing new technologies at New Oncology. Upon completion of his doctorate on the function of DNA polymerases, he carried out research on precursor molecules for new drugs at The Scripps Research Institute, CA, USA. He then worked for many years as a scientist at Illumina, the world market leader in the field of next generation sequencing.
Dr. Roopika Menon
Chief Diagnostic Officer
Roopika Menon leads the Diagnostics Department and is your contact for queries related to sample logistics, processing, and data analysis. She received her doctorate in the field of Molecular Biomedicine with a specialization in prostate cancer. With a strong publication record to her credit, she has been actively involved in setting up the diagnostic routines in the company.
Chief Information Officer
Thomas Franz leads the Information Technology Department and is your contact for IT-related inquiries. With more than 20 years of expertise in heterogeneous IT environments, he has been instrumental in setting up the IT systems and processes in the company.
Back to the top